第9回泌尿器画像診断・治療技術研究会　ベストポスターアワード 優秀賞
藤原 基裕、吉田 宗一郎、高原 太郎、吉富 香澄、相馬 貴彦、小林 正貴、中村 祐基、范 博、石川 雄大、福田 翔平、早稲田 悠馬、上原 翔、田中 一、横山 みなと、藤井 靖久. 第9回泌尿器画像診断・治療技術研究会（JSURT） 2022年8月6日

Nishizawa M, Kudo T, Kijima T, Fujii Y. Failed endovascular abdominal aortic aneurysm repair due to Mycobacterium bovis infection following intravesical bacillus Calmette-Gu ́erin therapy. J Vasc Surg Cases Innov Tech. 8(4); 807-812, 2022. PubMed

Yuan JH, Tanaka H, Patil D, Hakimi K, Soliman S, Meagher MF, Saidian A, Walia A, Dhanji S, Liu F, Afari J, Nguyen M, Wang L, Yasuda Y, Saito K, Fujii Y, Master V, Derweesh IH. Age-Related Differences in Oncological Outcomes in Renal Cell Carcinoma: Impact of Functional Conservation as Measured by Postoperative eGFR. Clin Genitourin Cancer. S1558-7673, 2022. PubMed

Nakamura Y, Fukushima H, Yoshitomi K, Soma T, Kobayashi M, Fan B, Fujiwara M, Ishikawa Y, Fukuda S, Waseda Y, Tanaka H, Yoshida S, Yokoyama M, Fujii Y. Significance of dorsal bladder neck involvement in predicting the progression of non-muscle-invasive bladder cancer. Int J Urol. 30(4); 381-388, 2022.PubMed

Yamaguchi Y, Yokoyama M, Takemoto A, Nakamura Y, Fukuda S, Uehara S, Tanaka H, Yoshida S, Matsuoka Y, Fujii Y. Succinate dehydrogenase-deficient malignant paraganglioma complicated by succinate dehydrogenase-deficient renal cell carcinoma. IJU case reports. 5(6); 480-483, 2022.PubMed

Fukagawa E, Yuasa T, Inamura K, Hamada K, Fujiwara M, Komai Y, Yonese J. De novo large-cell neuroendocrine carcinoma of the prostate: A case report and literature review. IJU Case Rep. 5(6); 505-510, 2022.PubMed

Yonese I, Ito M, Waseda Y, Kobayashi S, Toide M, Takazawa R, Koga F. Adverse Prognostic Impact of Diagnostic Ureterorenoscopy in a Subset of Patients with High-Risk Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. Cancers. 14(16); 3962, 2022.PubMed

Yamamoto S, Fukushima H, Fukuda S, Uehara S, Yasuda Y, Tanaka H, Yoshida S, Yokoyama M, Matsuoka Y, Fujii Y. Early cancer cachexia phenotype predicts survival of advanced urothelial cancer patients treated with pembrolizumab. Asia Pac J Clin Oncol. 18(4); 410-418, 2022.PubMed

Tanaka H, Fujii Y. Editorial Comment to Comprehensive assessments of immuno-oncology drug-based combination therapies as first-line treatment for advanced renal cell carcinoma Int J Urol. 29(8); 822-823, 2022.PubMed

Miyauchi M, Akashi T, Furukawa A, Uchida K, Tamura T, Ando N, Kirimura S, Shintaku H, Yamamoto K, Ito T, Miura K, Kayamori K, Ariizumi Y, Asakage T, Kudo A, Tanabe M, Fujii Y, Ishibashi H, Okubo K, Murakami M, Yamada T, Takemoto A, Bae Y, Eishi Y, Ohashi K. Endocr Pathol. PHOX2B is a Sensitive and Specific Marker for the Histopathological Diagnosis of Pheochromocytoma and Paraganglioma Endocr Pathol. 33(4); 506-518, 2022.PubMed

Toide M, Saito K, Yasuda Y, Tanaka H, Fukuda S, Patil D, Cotta BH, Patel SH, Master VA, Derweesh IH, Fujii Y. Prognostic Significance of C-reactive Protein in Patients with Non-metastatic Papillary Renal Cell Carcinoma: Results from the INternational Marker Consortium for Renal Cancer (INMARC) Cohort. Clin Genitourin Cancer. 20(4); 276-282, 2022.PubMed

Waseda Y, Takazawa R, Kobayashi M, Fuse H, Tamiya T. Different failure rates of insertion of 10/12-Fr ureteral access sheaths during retrograde intrarenal surgery in patients with and without stones. Investig Clin Urol. 63(4); 433-440, 2022.PubMed

Waseda Y, Takazawa R, Kobayashi M, Fuse H, Tamiya T. Risk factors and predictive model for incidence of difficult ureter during retrograde ureteroscopic lithotripsy. Int J Urol. 29(6); 542-546, 2022.PubMed

Waseda Y, Takazawa R. Re: Editorial Comment to Risk factors and predictive model for incidence of difficult ureter during retrograde ureteroscopic lithotripsy. Int J Urol. 29(6); 547, 2022.PubMed

Matsumoto S, Arita Y, Yoshida S, Fukushima H, Kimura K, Yamada I, Tanaka H, Yagi F, Yokoyama M, Matsuoka Y, Oya M, Tateishi U, Jinzaki M, Fujii Y. Utility of radiomics features of diffusion-weighted magnetic resonance imaging for differentiation of fat-poor angiomyolipoma from clear cell renal cell carcinoma: model development and external validation. Abdom Radiol. 47(6); 2178-2186, 2022.PubMed

Tanaka H, Fujii Y. Editorial Comment to Surgical and focal treatment for metastatic renal cell carcinoma: A literature review. Int J Urol. 29(6); 501-502, 2022.PubMed

Yoshitomi KK, Komai Y, Yamamoto T, Fukagawa E, Hamada K, Yoneoka Y, Fujiwara M, Fujiwara R, Oguchi T, Numao N, Yuasa T, Yamamoto S, Fukui I, Yonese J. Improving Accuracy, Reliability, and Efficiency of the RENAL Nephrometry Score With 3D Reconstructed Virtual Imaging. Urology. 164; 286-292, 2022.PubMed

Fujiwara M, Numao N, Yamamoto S, Ishikawa Y, Fujiwara R, Oguchi T, Komai Y, Matsuoka Y, Yuasa T, Yonese J. Predictive ability of prebiopsy magnetic resonance imaging and biopsy for side-specific negative lymph node metastasis at radical prostatectomy. Prostate. 82(8); 904-910, 2022.PubMed

Meagher MF, Patil D, Saito K, Javier-Desloges JF, Bradshaw AW, Patel SH, Cotta BH, Yasuda Y, Eldefrawy A, Ghali F, Nasseri R, Wan F, Fujii Y, Master V, Derweesh IH. Disparities in Cancer Specific and Overall Survival Outcomes in African Americans with Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC). Urology. 163; 164-176, 2022.PubMed

Matsuoka Y, Uehara S, Toda K, Fukushima H, Tanaka H, Yoshida S, Yokoyama M, Yoshimura R, Kihara K, Fujii Y. Focal brachytherapy for localized prostate cancer: 5.7-year clinical outcomes and a pair-matched study with radical prostatectomy. Urol Oncol. 40(4); 161, 2022.PubMed

Rathi N, Palacios DA, Abramczyk E, Tanaka H, Ye Y, Li J, Yasuda Y, Abouassaly R, Eltemamy M, Wee A, Weight C, Campbell SC. Predicting GFR after radical nephrectomy: the importance of split renal function. World J Urol. 40(4); 1011-1018, 2022.PubMed

Fujiwara M, Fujiwara R, Urasaki T, Oguchi T, Komai Y, Numao N, Yamamoto S, Yonese J, Yuasa T. Early Serum and Hematological Responses to Pembrolizumab Therapy as Predictors of Survival in Metastatic Urothelial Cancer. Anticancer Res. 42(4); 2045-2051, 2022.PubMed

Fujiwara M, Fujiwara R, Oguchi T, Komai Y, Numao N, Yamamoto S, Yonese J, Yuasa T. Clinical Outcome and Prognostic Variables of Second-line Therapy for Patients With Castration-resistant Prostate Cancer After Failure of First-line Androgen Receptor Axis-targeted Therapy. Anticancer Res. 42(4); 2123-2130, 2022.PubMed

Arita Y, Yoshida S, Kwee TC, Edo H, Kufukihara R, Shigeta K, Nagasaka M, Takeshita R, Okamura H, Ueda R, Ishii R, Okuda S, Fujii Y. Clinical utility of the Bosniak classification version 2019: Diagnostic value of adding magnetic resonance imaging to computed tomography examination. Eur J Radiol. 148; 110163, 2022.PubMed

Arita Y, Akita H, Fujiwara H, Hashimoto M, Shigeta K, Kwee TC, Yoshida S, Kosaka T, Okuda S, Oya M, Jinzaki M. Synthetic magnetic resonance imaging for primary prostate cancer evaluation: Diagnostic potential of a non-contrast-enhanced bi-parametric approach enhanced with relaxometry measurements. Eur J Radiol Open. 15(9); 100403, 2022.PubMed

Yoshida S, Fujii Y. Editorial Comment from Dr Yoshida and Dr Fujii to Role of Vesical Imaging-Reporting and Data System in predicting muscle-invasive bladder cancer: A diagnostic meta-analysis. Int J Urol. 29(3); 196, 2022.PubMed

Yoshida S, Matsushima H, Fujii Y. Classification of oligometastatic prostate cancer with additional consideration for hormone sensitivity. World J Urol . 40(3); 871-873, 2022.PubMed

Uchida Y, Yoshida S, Arita Y, Shimoda H, Kimura K, Yamada I, Tanaka H, Yokoyama M, Matsuoka Y, Jinzaki M, Fujii Y. Apparent Diffusion Coefficient Map-Based Texture Analysis for the Differentiation of Chromophobe Renal Cell Carcinoma from Renal Oncocytoma. Diagnostics. 12(4); 817, 2022.PubMed

Yoshida S, Takahara T, Arita Y, Toda K, Kimura K, Tanaka H, Yokoyama M, Matsuoka Y, Yoshimura R, Fujii Y. Impact of Progressive Site-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer on Subsequent Treatment Response. Cancer. 14(3); 567, 2022.PubMed

Kobayashi M, Waseda Y, Fuse H, Takazawa R. Variables measured on three-dimensional computed tomography are preferred for predicting the outcomes of shock wave lithotripsy. World journal of urology. 40(2); 569-575, 2022.PubMed

Kimura K, Yoshida S, Tsuchiya J, Yamada I, Tanaka H, Yokoyama M, Matsuoka Y, Yoshimura R, Tateishi U, Fujii Y. Usefulness of texture features of apparent diffusion coefficient maps in predicting chemoradiotherapy response in muscle-invasive bladder cancer. Eur Radiol. 32(1); 671-679, 2022.PubMed

Keiner C, Meagher M, Patil D, Saito K, Walia A, Liu F, Dutt R, Miller N, Dhanji S, Saidian A, Wan F, Yasuda Y, Fujii Y, Tanaka H, Master V, Derweesh I. Association of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and De Ritis ratio with mortality in renal cell carcinoma: A multicenter analysis. Front Oncol. 12; 995991, 2022.PubMed

Preedanan W, Suzuki K, Kondo T, Kobayashi M, Tanaka H, Ishioka J, Matsuoka Y, Fujii Y, Kumazawa I. Improvement of Urinary Stone Segmentation Using GAN-Based Urinary Stones Inpainting Augmentation. IEEE Access. 10; 115131-115142, 2022.doi

Rossi SH, Tanaka H, Usher-Smith JA, Bernhard JC, Fujii Y, Stewart GD. Kidney Cancer Screening and Epidemiology. Soci ́et ́e Internationale d'Urologie Journal. 3(6); 2022.doi

Uchida Y, Yokoyama M, Nakamura Y, Fukuda S, Uehara S, Tanaka H, Yoshida S, Matsuoka Y, Fujii Y. Assessment of erectile and ejaculatory functions after bladder-sparing therapy against muscle-invasive bladder cancer. J Sex Med. 19(5); S196-197, 2022. doi

Yoshida S, Takahara T, Arita Y, Toda K, Kimura K, Fujiwara M, Tanaka H, Yokoyama M, Matsuoka Y, Yoshimura R, Fujii Y. Patterns of recurrence in genuine and induced oligometastatic castration-resistant prostate cancer treated with progressive site-directed therapy. Int J Urol. 30(2); 204-210, 2023.PubMed

Arita Y, Yoshida S, Shigeta K, Kwee TC, Edo H, Okawara N, Hashimoto M, Ishii R, Ueda R, Mikami S, Fujiwara M, Waseda Y, Kikuchi E, Fujii YJinzaki M. Diagnostic Value of the Vesical Imaging-Reporting and Data System in Bladder Urothelial Carcinoma with Variant Histology. Eur Urol Oncol. 6(1); 99-102, 2023. PubMed

Arita Y, Yoshida S, Shigeta K, Kwee TC, Edo H, Okawara N, Hashimoto M, Ishii R, Ueda R, Mikami S, Fujiwara M, Waseda Y, Kikuchi E, Fujii Y, Jinzaki M. Diagnostic Value of the Vesical Imaging-Reporting and Data System in Bladder Urothelial Carcinoma with Variant Histology. Eur Urol Oncol. 6(1); 99-102, 2023. PubMed

Fujiwara R, Yuasa T, Yamamoto S, Fujiwara M, Takemura K, Urasaki T, Oki R, Komai Y, Oguchi T, Numao N, Yonese J. Geriatric Nutritional Risk Index as a Predictor of Prognosis in Metastatic Renal Cell Carcinoma Treated with Nivolumab. Nutr Cancer. 75(2); 670-677, 2023. PubMed

Chen W, Yokoyama M, Kobayashi M, Fan B, Fukuda S, Waseda Y, Tanaka H, Yoshida S, Ai M, Fushimi K, Nonomura N, Fujii Y. Trends of radical cystectomy and comparisons of surgical outcomes among surgical approaches focusing on robot-assisted radical cystectomy: A Japanese nationwide database study. Int J Urol. 30(3); 258-263, 2023.PubMed

Nguyen MV, Walia A, Saidian A, Puri D, Meagher MF, Hakimi K, Tanaka H, Patil D, Yasuda Y, Saito K, Dhanji S, Cerrato C, Narasimhan R, Perry J, Master V, Fujii Y, Derweesh IH. Impact of worsening surgically induced chronic kidney disease (CKD-S) in preoperative CKD-na ̈ıve patients on survival in renal cell carcinoma. BJU Int. 131(2); 219-226, 2023.PubMed